Abstract
The introduction of CRISPR/Cas has resulted in a strong impulse for the field of gene-targeted epigenome reprogramming. In this approach EpiEditors are applied in cells, which consist of a DNA-binding part for targeting and a functional part to induce chromatin modifications at targeted genome loci. The accumulating evidence of epigenetic reprogramming of a given genomic locus resulting in gene expression changes indicated causal relationships of epigenetic marks instructing gene expression and opened the field for mainstream applications. In this perspective, an overview of the current status of the field is provided, including its applications and future perspectives. The dependence of critical parameters like specificity, effectivity, and sustainability of epigenome editing on experimental settings and conditions including the expression levels and the duration of the expression of the EpiEditors, their DNA-binding affinity and specificity, and the cross talk between EpiEditors and cellular chromatin modifiers is discussed. Once established in fully functional “plug-and-play” mode, epigenome editing will allow to better understand epigenetic expression control and to translate such knowledge into therapeutic tools.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Allis CD, Jenuwein T (2016) The molecular hallmarks of epigenetic control. Nat Rev Genet 17(8):487–500. https://doi.org/10.1038/nrg.2016.59
Bannister AJ, Kouzarides T (2011) Regulation of chromatin by histone modifications. Cell Res 21(3):381–395. https://doi.org/10.1038/cr.2011.22
Schubeler D (2015) Function and information content of DNA methylation. Nature 517(7534):321–326. https://doi.org/10.1038/nature14192
Aiuti A, Roncarolo MG, Naldini L (2017) Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Mol Med 9(6):737–740. https://doi.org/10.15252/emmm.201707573
Kungulovski G, Jeltsch A (2016) Epigenome editing: state of the art, concepts, and perspectives. Trends Genet 32(2):101–113. https://doi.org/10.1016/j.tig.2015.12.001
Thakore PI, Black JB, Hilton IB, Gersbach CA (2016) Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nat Methods 13(2):127–137. https://doi.org/10.1038/nmeth.3733
Pulecio J, Verma N, Mejia-Ramirez E, Huangfu D, Raya A (2017) CRISPR/Cas9-based engineering of the epigenome. Cell Stem Cell 21(4):431–447. https://doi.org/10.1016/j.stem.2017.09.006
Turner BM (2012) The adjustable nucleosome: an epigenetic signaling module. Trends Genet 28(9):436–444. https://doi.org/10.1016/j.tig.2012.04.003
Henikoff S, Shilatifard A (2011) Histone modification: cause or cog? Trends Genet 27(10):389–396. https://doi.org/10.1016/j.tig.2011.06.006
de Groote ML, Verschure PJ, Rots MG (2012) Epigenetic editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Res 40(21):10596–10613. https://doi.org/10.1093/nar/gks863
Laufer BI, Singh SM (2015) Strategies for precision modulation of gene expression by epigenome editing: an overview. Epigenetics Chromatin 8:34. https://doi.org/10.1186/s13072-015-0023-7
Black JB, Adler AF, Wang HG, D’Ippolito AM, Hutchinson HA, Reddy TE, Pitt GS, Leong KW, Gersbach CA (2016) Targeted epigenetic remodeling of endogenous loci by CRISPR/Cas9-based transcriptional activators directly converts fibroblasts to neuronal cells. Cell Stem Cell 19(3):406–414. https://doi.org/10.1016/j.stem.2016.07.001
Amabile A, Migliara A, Capasso P, Biffi M, Cittaro D, Naldini L, Lombardo A (2016) Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing. Cell 167(1):219–232.e214. https://doi.org/10.1016/j.cell.2016.09.006
Liu XS, Wu H, Ji X, Stelzer Y, Wu X, Czauderna S, Shu J, Dadon D, Young RA, Jaenisch R (2016) Editing DNA methylation in the mammalian genome. Cell 167(1):233–247.e217. https://doi.org/10.1016/j.cell.2016.08.056
Stepper P, Kungulovski G, Jurkowska RZ, Chandra T, Krueger F, Reinhardt R, Reik W, Jeltsch A, Jurkowski TP (2017) Efficient targeted DNA methylation with chimeric dCas9-Dnmt3a-Dnmt3L methyltransferase. Nucleic Acids Res 45(4):1703–1713. https://doi.org/10.1093/nar/gkw1112
Huang YH, Su J, Lei Y, Brunetti L, Gundry MC, Zhang X, Jeong M, Li W, Goodell MA (2017) DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A. Genome Biol 18(1):176. https://doi.org/10.1186/s13059-017-1306-z
O’Geen H, Ren C, Nicolet CM, Perez AA, Halmai J, Le VM, Mackay JP, Farnham PJ, Segal DJ (2017) dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression. Nucleic Acids Res 45(17):9901–9916. https://doi.org/10.1093/nar/gkx578
Stolzenburg S, Beltran AS, Swift-Scanlan T, Rivenbark AG, Rashwan R, Blancafort P (2015) Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer. Oncogene. https://doi.org/10.1038/onc.2014.470
Kungulovski G, Nunna S, Thomas M, Zanger UM, Reinhardt R, Jeltsch A (2015) Targeted epigenome editing of an endogenous locus with chromatin modifiers is not stably maintained. Epigenetics Chromatin 8:12. https://doi.org/10.1186/s13072-015-0002-z
Xu GL, Bestor TH (1997) Cytosine methylation targetted to pre-determined sequences. Nat Genet 17(4):376–378. https://doi.org/10.1038/ng1297-376
Jeltsch A, Jurkowska RZ, Jurkowski TP, Liebert K, Rathert P, Schlickenrieder M (2007) Application of DNA methyltransferases in targeted DNA methylation. Appl Microbiol Biotechnol 75(6):1233–1240. https://doi.org/10.1007/s00253-007-0966-0
Snowden AW, Gregory PD, Case CC, Pabo CO (2002) Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo. Curr Biol 12(24):2159–2166
Li F, Papworth M, Minczuk M, Rohde C, Zhang Y, Ragozin S, Jeltsch A (2007) Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target genes. Nucleic Acids Res 35(1):100–112. https://doi.org/10.1093/nar/gkl1035
Siddique AN, Nunna S, Rajavelu A, Zhang Y, Jurkowska RZ, Reinhardt R, Rots MG, Ragozin S, Jurkowski TP, Jeltsch A (2013) Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity. J Mol Biol 425(3):479–491. https://doi.org/10.1016/j.jmb.2012.11.038
Falahi F, Huisman C, Kazemier HG, van der Vlies P, Kok K, Hospers GA, Rots MG (2013) Towards sustained silencing of HER2/neu in cancer by epigenetic editing. Mol Cancer Res 11(9):1029–1039. https://doi.org/10.1158/1541-7786.MCR-12-0567
Chen H, Kazemier HG, de Groote ML, Ruiters MH, Xu GL, Rots MG (2014) Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter. Nucleic Acids Res 42(3):1563–1574. https://doi.org/10.1093/nar/gkt1019
Maeder ML, Angstman JF, Richardson ME, Linder SJ, Cascio VM, Tsai SQ, Ho QH, Sander JD, Reyon D, Bernstein BE, Costello JF, Wilkinson MF, Joung JK (2013) Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat Biotechnol 31(12):1137–1142. https://doi.org/10.1038/nbt.2726
Cano-Rodriguez D, Rots MG (2016) Epigenetic editing: on the verge of reprogramming gene expression at will. Curr Genet Med Rep 4(4):170–179. https://doi.org/10.1007/s40142-016-0104-3
Pabo CO, Peisach E, Grant RA (2001) Design and selection of novel Cys2His2 zinc finger proteins. Annu Rev Biochem 70:313–340. https://doi.org/10.1146/annurev.biochem.70.1.313
Jamieson AC, Miller JC, Pabo CO (2003) Drug discovery with engineered zinc-finger proteins. Nat Rev Drug Discov 2(5):361–368. https://doi.org/10.1038/nrd1087
Geel TM, Ruiters MHJ, Cool RH, Halvic L, Voshart DC, Andrade Ruiz L, Niezen-Koning KE, Arimondo PB, Rots MG (2017) The past and presence of DNA targeting: from chemicals and DNA via proteins to RNA. Philos Trans Actions B:in press
Wolfe SA, Nekludova L, Pabo CO (2000) DNA recognition by Cys2His2 zinc finger proteins. Annu Rev Biophys Biomol Struct 29:183–212. https://doi.org/10.1146/annurev.biophys.29.1.183
Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S, Lahaye T, Nickstadt A, Bonas U (2009) Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326(5959):1509–1512. https://doi.org/10.1126/science.1178811
Bogdanove AJ, Voytas DF (2011) TAL effectors: customizable proteins for DNA targeting. Science 333(6051):1843–1846. https://doi.org/10.1126/science.1204094
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816–821. https://doi.org/10.1126/science.1225829
Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA (2013) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152(5):1173–1183. https://doi.org/10.1016/j.cell.2013.02.022
Pattanayak V, Ramirez CL, Joung JK, Liu DR (2011) Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods 8(9):765–770. https://doi.org/10.1038/nmeth.1670
Grimmer MR, Stolzenburg S, Ford E, Lister R, Blancafort P, Farnham PJ (2014) Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation. Nucleic Acids Res 42(16):10856–10868. https://doi.org/10.1093/nar/gku708
Hashimoto H, Wang D, Horton JR, Zhang X, Corces VG, Cheng X (2017) Structural basis for the versatile and methylation-dependent binding of CTCF to DNA. Mol Cell 66(5):711–720.e713. https://doi.org/10.1016/j.molcel.2017.05.004
Guilinger JP, Pattanayak V, Reyon D, Tsai SQ, Sander JD, Joung JK, Liu DR (2014) Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat Methods 11(4):429–435. https://doi.org/10.1038/nmeth.2845
Polstein LR, Perez-Pinera P, Kocak DD, Vockley CM, Bledsoe P, Song L, Safi A, Crawford GE, Reddy TE, Gersbach CA (2015) Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators. Genome Res 25(8):1158–1169. https://doi.org/10.1101/gr.179044.114
Kuscu C, Arslan S, Singh R, Thorpe J, Adli M (2014) Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol 32(7):677–683. https://doi.org/10.1038/nbt.2916
O’Geen H, Henry IM, Bhakta MS, Meckler JF, Segal DJ (2015) A genome-wide analysis of Cas9 binding specificity using ChIP-seq and targeted sequence capture. Nucleic Acids Res 43(6):3389–3404. https://doi.org/10.1093/nar/gkv137
Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung JK (2016) High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529(7587):490–495. https://doi.org/10.1038/nature16526
Konermann S, Brigham MD, Trevino AE, Hsu PD, Heidenreich M, Cong L, Platt RJ, Scott DA, Church GM, Zhang F (2013) Optical control of mammalian endogenous transcription and epigenetic states. Nature 500(7463):472–476. https://doi.org/10.1038/nature12466
Mercer AC, Gaj T, Sirk SJ, Lamb BM, Barbas CF 3rd (2014) Regulation of endogenous human gene expression by ligand-inducible TALE transcription factors. ACS Synth Biol 3(10):723–730. https://doi.org/10.1021/sb400114p
Zetsche B, Volz SE, Zhang F (2015) A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat Biotechnol 33(2):139–142. https://doi.org/10.1038/nbt.3149
Nihongaki Y, Kawano F, Nakajima T, Sato M (2015) Photoactivatable CRISPR-Cas9 for optogenetic genome editing. Nat Biotechnol 33(7):755–760. https://doi.org/10.1038/nbt.3245
Polstein LR, Gersbach CA (2015) A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nat Chem Biol 11(3):198–200. https://doi.org/10.1038/nchembio.1753
Chen T, Gao D, Zhang R, Zeng G, Yan H, Lim E, Liang FS (2017) Chemically controlled epigenome editing through an inducible dCas9 system. J Am Chem Soc 139(33):11337–11340. https://doi.org/10.1021/jacs.7b06555
Jeltsch A, Jurkowska RZ (2016) Allosteric control of mammalian DNA methyltransferases – a new regulatory paradigm. Nucleic Acids Res 44(18):8556–8575. https://doi.org/10.1093/nar/gkw723
Muller MM, Fierz B, Bittova L, Liszczak G, Muir TW (2016) A two-state activation mechanism controls the histone methyltransferase Suv39h1. Nat Chem Biol 12(3):188–193. https://doi.org/10.1038/nchembio.2008
Jiao L, Liu X (2015) Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2. Science 350(6258):aac4383. https://doi.org/10.1126/science.aac4383
Bintu L, Yong J, Antebi YE, McCue K, Kazuki Y, Uno N, Oshimura M, Elowitz MB (2016) Dynamics of epigenetic regulation at the single-cell level. Science 351(6274):720–724. https://doi.org/10.1126/science.aab2956
Elgin SC, Reuter G (2013) Position-effect variegation, heterochromatin formation, and gene silencing in Drosophila. Cold Spring Harb Perspect Biol 5(8):a017780. https://doi.org/10.1101/cshperspect.a017780
Cornu TI, Mussolino C, Cathomen T (2017) Refining strategies to translate genome editing to the clinic. Nat Med 23(4):415–423. https://doi.org/10.1038/nm.4313
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Rots, M.G., Jeltsch, A. (2018). Editing the Epigenome: Overview, Open Questions, and Directions of Future Development. In: Jeltsch, A., Rots, M. (eds) Epigenome Editing. Methods in Molecular Biology, vol 1767. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7774-1_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7774-1_1
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7773-4
Online ISBN: 978-1-4939-7774-1
eBook Packages: Springer Protocols